The appointment of counsel Vladimir Murovec as practice head at Osborne Clarke has ensured that the life sciences regulatory department has ‘become a top choice among life sciences businesses as they navigate EU market entry or face compliance hurdles'. The team utilises a threefold sector approach which focuses on biotech and pharma, digital health, and healthcare. Clients range from global businesses to fast-growth start-ups and market challengers.
Testimonials
Collated independently by Legal 500 research team.
‘Vladimir Murovec is a professional lawyer with in-house counsel experience. This is helpful in getting practical solutions.'
‘Highly knowledgeable team. Easy to approach and quick replies.’
‘The life sciences regulatory team is well embedded in the Brussels office's global service offering. This means that they can easily collaborate with other practices to deliver not only EU regulatory advice but also raise red flags or provide advice on data topics, IP protection or confidentiality issues, contract law and commercial aspects, etc in any cross-border health tech projects.'
‘Vladimir Murovec has unique experience in advising health tech and pharma businesses on the regulatory framework in which they operate and is a go-to EU lawyer for global life sciences businesses launching in Europe or experiencing challenges with regulators or notified bodies.'
'Vladimir Murovec has a quick understanding of new health technologies and products with a digital element. He provides sound, risk-based advice that is useful and actionable. I have recommended him to my peers in the industry due to the quality of his work.’
'The team is good at apprehending the issues and providing solutions in a timely manner.’
‘Vladimir Murovec brings a special blend of expertise to the table when it comes to guiding pharma companies through the EU regulatory maze. He's become a top choice among life sciences businesses as they navigate EU market entry or face compliance hurdles. He is well connected and provides seamless cross-border advice to global players in the pharmaceutical industry.’
‘The Osborne Clarke EU life sciences regulatory team is right at home in the heart of the Brussels office, making them a go-to team for a range of legal services. What makes them stand out in that space is that they're not just a tech or life sciences firm – they're both.'
Key clients
- Afflelou Group
- Alnylam Pharmaceuticals
- BePharBel Manufacturing
- Bone Therapeutics
- Coopervision
- Epstein, Becker & Green
- Medi-Market
- Novo Nordisk
- OncoDNA
- Sunrise
Work highlights
- Advising a global private equity fund on EU and domestic healthcare and medical device regulatory due diligence and potential acquisition of an international medical device business across ten European jurisdictions.
- Advising an international pharmaceutical business on the launch of a cross-border communication campaign around pipeline initiatives and disease awareness activities in compliance with EU pharmaceutical regulations.
- Advising a consumer health and cosmetics giant on the qualification of a beauty care technology as a product without an intended medical purpose under European medical devices regulations.
Practice head
The lawyer(s) leading their teams.
Vladimir Murovec